WSL
LENZ

Western Standard LLC’s LENZ Therapeutics LENZ Stock Holding History

Western Standard LLC’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,012
Closed -$455K – 36
2023
Q2 		$455K Sell
25,012
-45,758
-65% -$914K 0.39% 30
2023
Q1 		$1.21M Buy
+70,770
New +$1.14M 1.23% 17

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Western Standard LLC's LENZ Position: Q3 2023 in Review

Western Standard LLC sold out of LENZ Therapeutics (LENZ) in Q3 2023, closing a stake of 25,012 shares — an estimated $455K sold.

Western Standard LLC first reported a position in LENZ in Q1 2023 and held it in 2 quarters. The position peaked at $1.21M in Q1 2023. 67 funds tracked by Wall St. Rank hold LENZ as of Q3 2023.

  • Western Standard LLC reported no remaining LENZ Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Western Standard LLC sold 25,012 LENZ Therapeutics shares in Q3 2023, an estimated $455K.
  • Western Standard LLC first reported a position in LENZ Therapeutics in Q1 2023 and held it in 2 quarters.
  • Western Standard LLC's LENZ Therapeutics position peaked at $1.21M in Q1 2023.
  • 67 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2023.

Based on Western Standard LLC's 13F filing for Q3 2023, filed 14 Nov 2023.